These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 33416243)
21. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma. Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148 [TBL] [Abstract][Full Text] [Related]
22. Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib. Kang J; Chen HJ; Wang Z; Liu J; Li B; Zhang T; Yang Z; Wu YL; Yang JJ J Thorac Oncol; 2018 Apr; 13(4):e49-e53. PubMed ID: 29128427 [No Abstract] [Full Text] [Related]
23. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. Bousquet Mur E; Bernardo S; Papon L; Mancini M; Fabbrizio E; Goussard M; Ferrer I; Giry A; Quantin X; Pujol JL; Calvayrac O; Moll HP; Glasson Y; Pirot N; Turtoi A; Cañamero M; Wong KK; Yarden Y; Casanova E; Soria JC; Colinge J; Siebel CW; Mazieres J; Favre G; Paz-Ares L; Maraver A J Clin Invest; 2020 Feb; 130(2):612-624. PubMed ID: 31671073 [TBL] [Abstract][Full Text] [Related]
24. Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations. Nasu S; Shiroyama T; Morita S; Takata S; Takada H; Masuhiro K; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T Intern Med; 2018 Dec; 57(24):3643-3645. PubMed ID: 30146570 [TBL] [Abstract][Full Text] [Related]
25. Successful dacomitinib treatment after osimertinib resistance in a patient with lung adenocarcinoma. Kagohashi K; Shiozawa T; Miyazaki K; Satoh H Clin Respir J; 2021 Jul; 15(7):851-852. PubMed ID: 33728770 [No Abstract] [Full Text] [Related]
26. A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. Makimoto G; Ninomiya K; Kubo T; Sunami R; Kato Y; Ichihara E; Ohashi K; Rai K; Hotta K; Tabata M; Maeda Y; Kiura K Jpn J Clin Oncol; 2021 May; 51(6):956-965. PubMed ID: 33829270 [TBL] [Abstract][Full Text] [Related]
29. Clinical Efficacy of Osimertinib in a Patient Presenting a Double EGFR L747S and G719C Mutation. Grolleau E; Haddad V; Boissière L; Falchero L; Arpin D J Thorac Oncol; 2019 Jul; 14(7):e151-e153. PubMed ID: 31235042 [No Abstract] [Full Text] [Related]
30. Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival. Joo JW; Hong MH; Shim HS Lung Cancer; 2018 Jul; 121():12-17. PubMed ID: 29858020 [TBL] [Abstract][Full Text] [Related]
31. It Takes Two To Target: A Study in KRAS Dimerization. Nabet B; Gray NS Biochemistry; 2018 Apr; 57(16):2289-2290. PubMed ID: 29648795 [No Abstract] [Full Text] [Related]
32. Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report. Fang YF; Liu PC Thorac Cancer; 2021 Dec; 12(24):3429-3432. PubMed ID: 34729927 [TBL] [Abstract][Full Text] [Related]
33. Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases. Iams WT; Beckermann KE; Almodovar K; Hernandez J; Vnencak-Jones C; Lim LP; Raymond CK; Horn L; Lovly CM J Thorac Oncol; 2019 Mar; 14(3):e45-e48. PubMed ID: 30543839 [No Abstract] [Full Text] [Related]
34. Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation. Zheng LP; Chen LY; Liao XY; Xu ZH; Chen ZT; Sun JG BMC Cancer; 2018 Nov; 18(1):1070. PubMed ID: 30400855 [TBL] [Abstract][Full Text] [Related]
35. Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. Riedel R; Michels S; Heydt C; Siemanowski J; Kobe C; Bunck A; Schäfer S; Fischer RN; Scheffler M; Abdulla DSY; Nogová L; Koleczko S; Merkelbach-Bruse S; Büttner R; Wolf J Lung Cancer; 2019 Jul; 133():20-22. PubMed ID: 31200822 [TBL] [Abstract][Full Text] [Related]
36. EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors. Li C; Jia R; Liu H; Zhang B; Wang C Diagn Pathol; 2018 Aug; 13(1):49. PubMed ID: 30103780 [TBL] [Abstract][Full Text] [Related]
37. KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC. Niemantsverdriet M; Schuuring E; Elst AT; van der Wekken AJ; van Kempen LC; van den Berg A; Groen HJM J Thorac Oncol; 2018 Dec; 13(12):e249-e251. PubMed ID: 30467046 [No Abstract] [Full Text] [Related]
38. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer. van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441 [TBL] [Abstract][Full Text] [Related]
39. Response to the Combination of Osimertinib and Trametinib in a Patient With EGFR-Mutant NSCLC Harboring an Acquired BRAF Fusion. Dagogo-Jack I; Piotrowska Z; Cobb R; Banwait M; Lennerz JK; Hata AN; Digumarthy SR; Sequist LV J Thorac Oncol; 2019 Oct; 14(10):e226-e228. PubMed ID: 31558234 [No Abstract] [Full Text] [Related]